FI942244A - Inhibitorer för cellregleringsfaktorer och förfaranden för hindrande och minskande av ärrbildning - Google Patents

Inhibitorer för cellregleringsfaktorer och förfaranden för hindrande och minskande av ärrbildning Download PDF

Info

Publication number
FI942244A
FI942244A FI942244A FI942244A FI942244A FI 942244 A FI942244 A FI 942244A FI 942244 A FI942244 A FI 942244A FI 942244 A FI942244 A FI 942244A FI 942244 A FI942244 A FI 942244A
Authority
FI
Finland
Prior art keywords
methods
cell regulatory
decorin
present
regulatory factor
Prior art date
Application number
FI942244A
Other languages
English (en)
Finnish (fi)
Other versions
FI942244A0 (sv
Inventor
Erkki I Ruoslahti
Michael T Longaker
David J Whitby
John R Harper
Michael D Pierschbacher
Wayne A Border
Original Assignee
Jolla Cancer Res Found
Univ California
Univ Utah
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jolla Cancer Res Found, Univ California, Univ Utah filed Critical Jolla Cancer Res Found
Publication of FI942244A0 publication Critical patent/FI942244A0/sv
Publication of FI942244A publication Critical patent/FI942244A/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electroluminescent Light Sources (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI942244A 1991-11-14 1994-05-13 Inhibitorer för cellregleringsfaktorer och förfaranden för hindrande och minskande av ärrbildning FI942244A (sv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79219291A 1991-11-14 1991-11-14
US88234592A 1992-05-13 1992-05-13
PCT/US1992/009871 WO1993009800A1 (en) 1991-11-14 1992-11-13 Inhibitors of cell regulatory factors and methods for preventing or reducing scarring

Publications (2)

Publication Number Publication Date
FI942244A0 FI942244A0 (sv) 1994-05-13
FI942244A true FI942244A (sv) 1994-07-06

Family

ID=27121246

Family Applications (1)

Application Number Title Priority Date Filing Date
FI942244A FI942244A (sv) 1991-11-14 1994-05-13 Inhibitorer för cellregleringsfaktorer och förfaranden för hindrande och minskande av ärrbildning

Country Status (10)

Country Link
EP (2) EP0667784B1 (sv)
JP (1) JPH07504886A (sv)
AT (1) ATE233568T1 (sv)
AU (1) AU673506B2 (sv)
CA (1) CA2123418A1 (sv)
DE (1) DE69232946T2 (sv)
ES (1) ES2188585T3 (sv)
FI (1) FI942244A (sv)
NO (1) NO941821L (sv)
WO (1) WO1993009800A1 (sv)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834444A (en) * 1991-07-03 1998-11-10 Hyal Pharmaceutical Corporation Hyaluronic acid and salts thereof inhibit arterial restenosis
ATE179712T1 (de) * 1993-03-01 1999-05-15 Glycan Pharm Inc Analoge für spezifische oligosaccharid-protein- wechselwirkungen und ihre verwendungen
ATE315939T1 (de) * 1993-11-19 2006-02-15 Univ Sydney Verfahren zur prophylaxe oder kontrolle des katarakts
GB2304045A (en) † 1995-08-04 1997-03-12 Univ Manchester Betaglycan compositions for promoting the healing of wounds and fibrotic diseases
US7763580B2 (en) 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
AU771635B2 (en) 1999-01-05 2004-04-01 American National Red Cross, The Methods for treating conditions associated with the accumulation of excess extracellular matrix
AU2008200019B2 (en) * 1999-01-05 2009-10-08 American National Red Cross Methods for treating conditions associated with the accumulation of excess extracellular matrix
WO2002068647A2 (en) * 2001-01-16 2002-09-06 Curagen Corporation Proteins, polynucleotides encoding them and methods of using the same
CN1506042A (zh) * 2002-12-11 2004-06-23 苏加璐 使用来自胎儿细胞和组织的化合物改善皮肤状况的方法和组合物
GB0309064D0 (en) 2003-04-22 2003-05-28 Univ Manchester Modified peptides and their uses
EP2862867A3 (en) 2005-10-25 2015-08-05 The Johns Hopkins University Methods and compositions for the treatment of Marfan syndrome and associated disorders
EP2230252A1 (en) 2006-03-13 2010-09-22 The Johns Hopkins University Augmentation of endothelial thromboresistance
ES2538265T3 (es) 2006-10-03 2015-06-18 Genzyme Corporation Anticuerpos contra TGF-beta para uso en el tratamiento de lactantes con riesgo de desarrollar displasia broncopulmonar
US10016452B2 (en) 2008-05-01 2018-07-10 The Regents Of The University Of California Fibromodulin formulation for reducing corneal scarring
KR100983182B1 (ko) * 2009-08-14 2010-09-20 (주)엔솔테크 신규 펩타이드 및 그 용도
CN103429732B (zh) 2010-12-27 2015-09-16 Lsip基金运营联合公司 iPS细胞及其制造方法
EP2686335B1 (en) * 2011-03-14 2018-04-25 Catalent Pharma Solutions, LLC Decorin compositions and use thereof
US20140308275A1 (en) 2011-07-27 2014-10-16 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods for diagnosing and treating myhre syndrome
CA2853484C (en) 2011-10-26 2018-08-21 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
US20150044178A1 (en) 2011-12-28 2015-02-12 Kyoto Prefectural Public University Corporation Normalization of culture of corneal endothelial cells
CA2907944C (en) * 2013-04-22 2020-11-03 Catalent Pharma Solutions, Llc Veterinary decorin compositions and use thereof
EP3064222B1 (en) 2013-10-31 2020-10-21 Kyoto Prefectural Public University Corporation Therapeutic drug comprising tgf-beta signal inhibitor for diseases related to endoplasmic reticulum cell death in corneal endothelium
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
WO2024158300A1 (en) * 2023-01-27 2024-08-02 Aroa Biosurgery Limited Methods and agents for treating soft tissue inflammation and associated diseases and conditions
WO2024158299A1 (en) * 2023-01-27 2024-08-02 Aroa Biosurgery Limited Methods and agents for treating tissue ischemia and associated diseases and conditions
WO2024158298A1 (en) * 2023-01-27 2024-08-02 Aroa Biosurgery Limited Methods and agents for treating respiratory inflammation and associated diseases and conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2887325B2 (ja) * 1988-06-28 1999-04-26 ラ ホヤ キャンサー リサーチ ファウンデーション デコリンによる細胞増殖の抑制
AU628910B2 (en) * 1988-12-20 1992-09-24 La Jolla Cancer Research Foundation Polypeptide-polymer conjugates active in wound healing
WO1991010727A1 (en) * 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing

Also Published As

Publication number Publication date
ATE233568T1 (de) 2003-03-15
AU3138593A (en) 1993-06-15
EP1230929A1 (en) 2002-08-14
DE69232946T2 (de) 2003-12-18
NO941821D0 (no) 1994-05-13
EP0667784A1 (en) 1995-08-23
FI942244A0 (sv) 1994-05-13
WO1993009800A1 (en) 1993-05-27
NO941821L (no) 1994-07-14
JPH07504886A (ja) 1995-06-01
ES2188585T3 (es) 2003-07-01
DE69232946D1 (de) 2003-04-10
EP0667784B1 (en) 2003-03-05
CA2123418A1 (en) 1993-05-27
AU673506B2 (en) 1996-11-14

Similar Documents

Publication Publication Date Title
FI942244A0 (sv) Inhibitorer för cellregleringsfaktorer och förfaranden för hindrande och minskande av ärrbildning
DE69331832D1 (de) Diagnostische verfahren und pharmazeutische zusammensetzungen auf der basis von notch-proteinen und nukleinsäuren
DE69131847D1 (de) Verwendung von kupfer enthaltenden wirkstoffen zur beschleunigung der wundheilung
AU2987695A (en) Interruption of binding of mdm2 and p53 protein and therapeutic application thereof
BR9507758A (pt) Fração de copolímero-1 e composição para o tratamento de esclerose múltipla
KR900007870A (ko) 브라디키닌 길항 작용을 갖는 펩티드
BG103594A (en) Stable liquid interferon compositions
PT792287E (pt) Analogos peptidicos da proteina basica da mielina humana
ATE400294T1 (de) Neue antimikrobielle polypeptide und verfahren für ihre verwendung.
SE9503679D0 (sv) Antioxidants
DK0845034T3 (da) Peptid med pronociceptive egenskaber
KR960004366A (ko) 합성 펩타이드 유도체 및 이의염
EP0524737A3 (en) Protein s. polypeptides and anti-peptide antibodies that inhibit protein s binding to c4b binding protein, diagnostic systems and therapeutic methods
Ayad et al. Type VI collagen and glycoprotein MFPI are distinct components of the extracellular matrix.
WO1997014966B1 (en) Method of activating a novel ligand regulatory pathway
DK0422215T3 (da) Antibakterielle peptider og antimalariapeptider
DE69809785D1 (de) Verwendung eines retinoidids zur in vivo erhöhung der entkopplung des ucp2 proteins
ES2097931T3 (es) Nueva proteina inhibidora de trombina a partir de chinches cazadoras.
KR100371976B1 (ko) 혈장헤파린결합단백질-70
US3992529A (en) Method of treating excessive fibrinolysis with synthetically modified trypsin inhibitors
HUP9601528A2 (hu) Véralvadásgátló hatású peptidszármazékok és a vegyületeket tartalmazó gyógyszerkészítmények
DE60212352D1 (de) Peptide zur behandlung von wundkontraktion
KR970701732A (ko) 펩신 방출을 억제하기 위한 펩티드(Peptides Inhibiting the Release of Pepsin)
ITFI930172A1 (it) Immunotossine contenenti proteine rip purificate da saponaria ocymoides e vaccaria pyramidata

Legal Events

Date Code Title Description
FD Application lapsed